Juvenile Arthritis

Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the June issue, which is led by a cover story on pediatric rheumatology workforce shortage concerns.

Patients with childhood systemic lupus erythematosus who receive care that closely adheres to quality metrics demonstrate better outcomes, according to data published in Arthritis Care & Research.

The field of pediatric rheumatology is at a crossroads.

There is “wide variation” in the way clinicians measure and report the physician’s global assessment of disease activity in patients with juvenile idiopathic arthritis, according to data published in Rheumatology.

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

Conventional memory B cells with low CXCR5 levels and CXCR5 T-helper 2 memory cells are potential biomarkers of juvenile dermatomyositis disease activity, according to data published in Arthritis & Rheumatology.

Remission should be the primary goal for patients with childhood-onset systemic lupus erythematosus, according to new points to consider for treat-to-target endorsed by the Pediatric Rheumatology European Society.

Patients with juvenile idiopathic arthritis do not appear to have an increased risk for anxiety or depression, compared with the general population, according to data published in Pediatric Rheumatology.

In patients with juvenile fibromyalgia, pain distribution throughout the body may be less important for clinical outcomes and impairment than other factors, according to data published in Arthritis Care & Research.

It is crucial that patients with juvenile arthritis stay active throughout their childhood for a better chance at building stronger bones, according to DMOS Orthopaedic Centers.